202 related articles for article (PubMed ID: 20961309)
1. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.
Pavlakovic H; Becker J; Albuquerque R; Wilting J; Ambati J
Ann N Y Acad Sci; 2010 Oct; 1207 Suppl 1(Suppl 1):E7-15. PubMed ID: 20961309
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
3. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
4. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.
Albuquerque RJ; Hayashi T; Cho WG; Kleinman ME; Dridi S; Takeda A; Baffi JZ; Yamada K; Kaneko H; Green MG; Chappell J; Wilting J; Weich HA; Yamagami S; Amano S; Mizuki N; Alexander JS; Peterson ML; Brekken RA; Hirashima M; Capoor S; Usui T; Ambati BK; Ambati J
Nat Med; 2009 Sep; 15(9):1023-30. PubMed ID: 19668192
[TBL] [Abstract][Full Text] [Related]
5. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity.
Singh N; Tiem M; Watkins R; Cho YK; Wang Y; Olsen T; Uehara H; Mamalis C; Luo L; Oakey Z; Ambati BK
Blood; 2013 May; 121(20):4242-9. PubMed ID: 23476047
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
8. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
9. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
11. Lymphangiogenic growth factors, receptors and therapies.
Lohela M; Saaristo A; Veikkola T; Alitalo K
Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
[TBL] [Abstract][Full Text] [Related]
12. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
13. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
Wirzenius M; Tammela T; Uutela M; He Y; Odorisio T; Zambruno G; Nagy JA; Dvorak HF; Ylä-Herttuala S; Shibuya M; Alitalo K
J Exp Med; 2007 Jun; 204(6):1431-40. PubMed ID: 17535974
[TBL] [Abstract][Full Text] [Related]
14. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.
Jones D; Xu Z; Zhang H; He Y; Kluger MS; Chen H; Min W
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2553-61. PubMed ID: 20864667
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.
Kaza E; Ablasser K; Poutias D; Griffiths ER; Saad FA; Hofstaetter JG; del Nido PJ; Friehs I
Cardiovasc Res; 2011 Feb; 89(2):410-8. PubMed ID: 20935166
[TBL] [Abstract][Full Text] [Related]
16. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
[TBL] [Abstract][Full Text] [Related]
17. Recombinant canstatin inhibits VEGF-A-induced lymphangiogenesis and metastasis in an oral squamous cell carcinoma SCC-VII animal model.
Hwang-Bo J; Park JH; Bae MG; Chung IS
Cancer Med; 2016 Oct; 5(10):2977-2988. PubMed ID: 27650585
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
19. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
